Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PAX5
REST API REST API
Homo sapiens
PAX5 is differentially expressed in 237 experiments: 83 organism parts: tonsil, dorsal root ganglion, ... (81 more);, 193 disease states: normal, colorectal adenocarcinoma, ... (191 more);, 88 cell types 333 cell lines 29 compound treatments and 76 other conditions.
Synonyms BSAP
Orthologs pax5 (Danio rerio)   F1NKU4_CHICK (Gallus gallus)   F6WAV5_CIOIN (Ciona intestinalis)   F6VTG6_CIOIN (Ciona intestinalis)   Pax5 (Mus musculus)   F1MWQ4_BOVIN (Bos taurus)   RGD1565236 (Rattus norvegicus)   sv (Drosophila melanogaster)   pax5 (Xenopus laevis)   PAX5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term humoral immune response, DNA binding, protein binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, spermatogenesis, transcription from RNA polymerase II promoter, cell differentiation, multicellular organismal development, nucleus, nervous system development, negative regulation of transcription from RNA polymerase II promoter, organ morphogenesis, negative regulation of histone H3-K9 methylation, sequence-specific DNA binding transcription factor activity
InterPro Term Paired_box_N, Pax2_C
UniProt Accession Q6S730, Q6S732, Q6S731, Q02548, C0KTG0, C0KTE1, C0KTE2, C0KTE3, C0KTE4, C0KTE5, C0KTE9, C0KTF6, C0KTF9, C0KTF7, C0KTF8, E7EQT0, E7ERW5, E7ES87, E7ERK2, E3W992, Q5SFM2
Search EB-eye ENSG00000196092
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-GEOD-7224, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (25 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-5823, E-GEOD-20081, E-GEOD-3529
MCF-10A
2
E-TABM-420, E-GEOD-14990
MCF7
2
E-GEOD-5258, E-MTAB-37
HL-60
1
2
E-GEOD-24147, E-GEOD-5258, E-MTAB-37
ew24 cell line, lentivirus treated
1
E-MTAB-62
Caki2
1
E-MTAB-37
327 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-120, E-GEOD-360, E-GEOD-13909, E-GEOD-20677, ... (43 experiments)

Factor Value U/D Experiments
2
2
E-TABM-145, E-TABM-130
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
hematopoietic stem cell
1
E-MEXP-1403
CD34+ hematopoietic stem cell
1
E-MEXP-1546
82 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-1869, E-MEXP-2069, ... (44 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-MTAB-37, E-GEOD-4412, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
chronic lymphocytic leukemia
2
E-GEOD-6691, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
lymphoma
2
E-MTAB-62, E-MTAB-37
melanoma
2
E-MTAB-37, E-MTAB-62
187 more value(s).


Compound treatment

studied in E-GEOD-7400, E-TABM-782, E-GEOD-697, E-GEOD-3720, E-GEOD-5824, ... (19 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-5824, E-GEOD-412, E-GEOD-2803, E-GEOD-4600, E-MEXP-1958, ... (9 experiments)
poly(I:C)
1
E-MEXP-1230
U0126
1
E-GEOD-697
vanadium pentoxide
1
E-GEOD-5339
glucose
1
E-MEXP-941
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
23 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
39
2
1
E-GEOD-3494


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-22513, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-1561, E-GEOD-1751 ... (5 experiments)

Environmental stress
studied in E-GEOD-3720, E-GEOD-4086

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-17476, E-TABM-868, E-TABM-601, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-MEXP-1446, E-MEXP-2146, E-GEOD-20505 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-MEXP-1648, ... (28 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-512

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-22229, E-GEOD-19703, E-GEOD-5824, E-GEOD-5820, E-GEOD-4600, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-GEOD-2666

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-TABM-43, E-GEOD-4922

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.261 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM